Multiple Myeloma Frontline Horizon: Quads, Bispecifics, and Breakthroughs

Experts review groundbreaking insights from review the 2023 American Society of Hematology Annual Meeting and Exposition (ASH 2023) and discuss the paradigm shift in myeloma frontline treatments, exploring quads, bispecifics, and the dynamic evolution of therapeutic approaches.

Related Keywords

Joshua Richter ,Rafat Abonour ,Peer Exchange ,Faith Davies ,Amrita Krishnan ,Multiple Myeloma ,Myeloma Treatment ,Newly Diagnosed Patients ,Mrd Negative Remission ,Therapeutic Goals ,Toxicity Management ,Individualized Approach ,Quadruplet Therapy ,Frailty Assessments ,Clinical Trials ,Treatment Regimens ,Myeloma Induction ,Transplant Ineligible ,Quad Regimens ,Deep Remission ,Maintenance Therapy ,